Cited by 166Redox biology and oxidative stressNeutrophil, Myeloperoxidase and Oxidative MechanismsNitric Oxide and Endothelin Effects

Therapeutic potential of nadph oxidase 1/4 inhibitors

Open access
Teixeira, G, Szyndralewiez, C, Molango, S, Carnesecchi, S, Heitz, F, Wiesel, P, Wood, J M·2017·British Journal of Pharmacology

Abstract

The NADPH oxidase (NOX) family of enzymes produces ROS as their sole function and is becoming recognized as key modulators of signal transduction pathways with a physiological role under acute stress and a pathological role after excessive activation under chronic stress. The seven isoforms differ in their regulation, tissue and subcellular localization and ROS products. The most studied are NOX1, 2 and 4. Genetic deletion of NOX1 and 4, in contrast to NOX2, has revealed no significant spontaneous pathologies and a pathogenic relevance of both NOX1 and 4 across multiple organs in a wide range of diseases and in particular inflammatory and fibrotic diseases. This has stimulated interest in NOX inhibitors for therapeutic application. GKT136901 and GKT137831 are two structurally related compounds demonstrating a preferential inhibition of NOX1 and 4 that have suitable properties for in vivo studies and have consequently been evaluated across a range of disease models and compared with gene deletion. In contrast to gene deletion, these inhibitors do not completely suppress ROS production, maintaining some basal level of ROS. Despite this and consistent with most gene deletion studies, these inhibitors are well tolerated and slow or prevent disease progression in a range of models of chronic inflammatory and fibrotic diseases by modulating common signal transduction pathways. Clinical trials in patients with GKT137831 have demonstrated excellent tolerability and reduction of various markers of chronic inflammation. NOX1/4 inhibition may provide a safe and effective therapeutic strategy for a range of inflammatory and fibrotic diseases. Linked Articles: This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13532

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • No direct antioxidative side effects of GKT137831 have been reported so far, highlighting it as the most promising inhibitor for Nox enzymes in vitro and in vivo.

    “In contrast, so far no direct antioxidative side effects of GKT 137831 were reported [392] highlighting this substance as the most promising inhibitor for Nox enzymes not only in vitro but also in vivo [94,409,411,412,413,414].”

    From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [392]

  • GKT136901 and GKT137831 inhibit Nox1, Nox4 and Nox5 and in higher concentrations also Nox2, Duox1, Duox2, and XO.

    “Both compounds inhibit Nox1, Nox4 and Nox5 and in higher concentrations also Nox2, Duox1, Duox2 [406,407,408,409], and XO [392,393,408,409].”

    From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [392]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 224 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Wiesel PHL, 2012, American Society of Nephrology Kidney Week

Cited by

Sorted by citations

Authors
Teixeira, G., Szyndralewiez, C., Molango, S., Carnesecchi, S., Heitz, F., Wiesel, P., & Wood, J. M.
Affiliations
  • Evotec (Germany) (DE)
  • Genkyotex (Switzerland) (CH)
  • Genkyotex SA Plan les Ouates Switzerland
  • Inovaid Biel‐Benken Switzerland
Corresponding author
Wood, J M
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2016-07-14
Volume
174
Issue
12
Pages
1647-1669
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2414686680
Cited by
163
References
224
Citations by year
2026: 10 · 2025: 13 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 28 · 2019: 17 · 2018: 22 · 2017: 16 · 2016: 5 · 2015: 1
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
Keywords
NADPH oxidase, NOX1, NOX4, NOX2, reactive oxygen species, NADPH oxidase inhibitors, GKT137831, chronic inflammation, fibrotic diseases, redox signaling, signal transduction, oxidative stress
MeSH terms
NADPH Oxidase 1, NADPH Oxidase 2, Animals, Anti-Inflammatory Agents, Enzyme Inhibitors, Fibrosis, Humans, Inflammation, Pyrazoles, Pyridines, Pyridones, Pyrazolones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review